Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples